Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, was featured in a recent article discussing its development of a vaccine candidate known as RiVax(R) to protect against ricin exposure. These efforts position the company at the center of biodefense preparedness as public awareness of ricin’s lethality grows. “In a counter-terrorism operation in India, authorities recently foiled a ricin plot, underscoring how easily accessible castor beans can be transformed into the deadly toxin using common tools such as a coffee grinder. The report is a stark reminder of ricin’s accessibility and the pressing need for effective countermeasures,” the article reads. “RiVax’s durability, evidenced by thermostability and strong protective efficacy in animal models, could allow for strategic stockpiling in national stockpiles and rapid deployment to first responders, military personnel and vulnerable civilian populations should a ricin incident occur. Continued development and regulatory progression of the vaccine may also inform broader strategies for biodefense and emergency readiness in a world where accessible biological threats continue to challenge health security systems.”
For further information, visit the company’s website at www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer